2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT

Open source

DOI: 10.1093/cid/ciaf424
Published: 2026 Jan 16
Container: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/cid/ciaf424,
  title = {2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.},
  author = {Bhimraj A and Falck-Ytter Y and Baden LR and Bedimo R and Cawcutt K and Cheng VC and Chew KW and Chiotos K and Daar ES and Dzierba AL and Glidden DV and Hardy EJ and Johnson S and Kim AY and Li JZ and MacBrayne C and Martin GS and Nadig N and Nakamura MM and Pearson JC and Riley L and Shafer RW and Shoham S and Shumaker AH and Tebas P and Tien PC and Loveless J and Morgan RL and Gandhi RT},
  year = {2026},
  journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  doi = {10.1093/cid/ciaf424},
  url = {https://doi.org/10.1093/cid/ciaf424}
}

RIS

TY  - JOUR
TI  - 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.
AU  - Bhimraj A
AU  - Falck-Ytter Y
AU  - Baden LR
AU  - Bedimo R
AU  - Cawcutt K
AU  - Cheng VC
AU  - Chew KW
AU  - Chiotos K
AU  - Daar ES
AU  - Dzierba AL
AU  - Glidden DV
AU  - Hardy EJ
AU  - Johnson S
AU  - Kim AY
AU  - Li JZ
AU  - MacBrayne C
AU  - Martin GS
AU  - Nadig N
AU  - Nakamura MM
AU  - Pearson JC
AU  - Riley L
AU  - Shafer RW
AU  - Shoham S
AU  - Shumaker AH
AU  - Tebas P
AU  - Tien PC
AU  - Loveless J
AU  - Morgan RL
AU  - Gandhi RT
PY  - 2026
JO  - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
DO  - 10.1093/cid/ciaf424
UR  - https://doi.org/10.1093/cid/ciaf424
ER  -

APA

A, B., Y, F., LR, B., R, B., K, C., VC, C., KW, C., K, C., ES, D., AL, D., DV, G., EJ, H., S, J., AY, K., JZ, L., C, M., GS, M., N, N., MM, N., JC, P., L, R., RW, S., S, S., AH, S., P, T., PC, T., J, L., RL, M., & RT, G. (2026). 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciaf424

Source records

pubmed · retrieved 2026-09-27T07:52:47.888Z